Low-dose prazosin in combination with 5-HT6 antagonist PRX-07034 has antipsychotic effects

Canadian Journal of Physiology and Pharmacology

Volumn 93, Issue 1, 2014, Pages 13-21

  Abraham, Renny ^a,b   Nirogi, Ramakrishna ^a   Shinde, Anil ^a   Irupannanavar, Shantaveer ^a  

^a SUVEN LIFE SCIENCES LTD   (India)

^b JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY   (India)

Author keywords

Object recognition task; Open field; Prepulse inhibition; Schizophrenia; Stereotypy assay

Indexed keywords

BRAIN MONOAMINE; DIZOCILPINE MALEATE; HALOPERIDOL; PRAZOSIN; SEROTONIN; SEROTONIN 6 ANTAGONIST; UNCLASSIFIED DRUG; [N [1 (5 CHLORORO 2,3 DIMETHOXYPHENYL)ETHYL] 2 METHYLSULPHONYL 5 PIPERAZIN 1 YL]; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; SEROTONIN 6 RECEPTOR; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR;

AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN LEVEL; CATALEPSY; CONTROLLED STUDY; LOW DRUG DOSE; MALE; MEMORY; NONHUMAN; OPEN FIELD TEST; PREFRONTAL CORTEX; PREPULSE INHIBITION; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; RAT; STEREOTYPY; ANIMAL; DRUG COMBINATION; DRUG EFFECTS; PHYSIOLOGY; WISTAR RAT;

ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; ANIMALS; ANTIPSYCHOTIC AGENTS; DRUG THERAPY, COMBINATION; MALE; MEMORY; PRAZOSIN; PREPULSE INHIBITION; RATS; RATS, WISTAR; RECEPTORS, SEROTONIN; SEROTONIN ANTAGONISTS;

EID: 84920696250     PISSN: 00084212     EISSN: 12057541     Source Type: Journal    
DOI: 10.1139/cjpp-2014-0254     Document Type: Article

References (52)

1. Adams, W., and van den Buuse, M. 2011.Hippocampal serotonin depletion facilitates the enhancement of prepulse inhibition by risperidone: possible role of 5-HT(2C) receptors in the dorsal hippocampus. Neuropharmacology, 61(3): 458–467. doi:10.1016/j.neuropharm.2011.03.018.PMID:21477601.
2. Al Amin, H.A., Shannon, W.C., Weinberger, D.R., and Lipska, B.K. 2001.Delayed onset of enhanced MK-801-induced motor hyperactivity after neonatal lesions of the rat ventral hippocampus. Biol. Psychiatry, 49(6): 528–539. doi:10.1016/S0006-3223(00)00968-9.PMID:11257238.
3. Alsene, K.M., Fallace, K., and Bakshi, V.P. 2010.Ventral striatal noradrenergic mechanisms contribute to sensorimotor gating deficits induced by amphetamine. Neuropsychopharmacology, 35(12): 2346–2356. doi:10.1038/npp.2010.106.PMID:20686455.
4. Arnt, J., and Olsen, C.K. 2011. 5-HT6 receptor ligands and their antipsychotic potential. Int. Rev. Neurobiol. 96: 141–61. doi:10.1016/B978-0-12-385902-0.00006-1.PMID:21329787.
5. Bakshi, V.P., and Geyer, M.A. 1997.Phencyclidine-induced deficits in prepulse inhibition of startle are blocked by prazosin, an alpha-1 noradrenergic antagonist. J. Pharmacol. Exp. Ther. 283(2): 666–674.PMID:9353384.
6. Baldessarini, R.J., and Tarazi, F.I. 2010.Pharmacotherapy of psychosis and mania. In Goodman & Gilman's The Pharmacological Basis of Therapeutics, 12th ed. Edited by L. Brunton, B. Chabner, and B. Knollman. McGraw-Hill Professional.
7. Bekinschtein, P., Renner, M.C., Gonzalez, M.C., and Weisstaub, N. 2013.Role of medial prefrontal cortex serotonin 2A receptors in the control of retrieval of recognition memory in rats. J. Neurosci. 33(40): 15716–15725. doi:10.1523/ JNEUROSCI.2087-13.2013.PMID:24089480.
8. Borison, R.L. 1996.The role of cognition in the risk–benefit and safety analysis of antipsychotic medication. Acta Psychiatr. Scand. Suppl. 389: 5–11.PMID: 8985471.
9. Bortolozzi, A., and Artigas, F. 2003.Control of 5-hydroxytryptamine release in the dorsal raphe nucleus by the noradrenergic system in rat brain. Role of alpha-adrenoceptors.Neuropsychopharmacology,28(3):421–434.doi:10.1038/sj.npp.1300061.PMID:12629522.
10. Cruz, D.A., Eggan, S.M., Azmitia, E.C., and Lewis, D.A. 2004.Serotonin1A receptors at the axon initial segment of prefrontal pyramidal neurons in schizophrenia. Am. J. Psychiatry, 161(4): 739–742. doi:10.1176/appi.ajp.161.4.739.PMID:15056522.
11. Eyhani-Rad, S., Mohajjel Nayebi, A, Mahmoudi, J., Samini, M., and Babapour, V. 2012.Role of 5-hydroxytryptamine 1A receptors in 6-hydroxydopmaineinduced catalepsy-like immobilization in rats: a therapeutic approach for treating catalepsy of Parkinson's Disease. Iran. J. Pharm. Res. 11(4): 1175–1181.PMID:24250551.
12. Fejgin, K., Palsson, E., Wass, C., Svensson, L., and Klamer, D. 2008.Nitric oxide signaling in the medial prefrontal cortex is involved in the biochemical and behavioral effects of phencyclidine. Neuropsychopharmacology, 33(8): 1874–1883. doi:10.1038/sj.npp.1301587.PMID:17895915.
13. Fijał, K., Popik, P., and Nikiforuk, A. 2014.Co-administration of 5-HT6 receptor antagonists with clozapine, risperidone, and a 5-HT2A receptor antagonist: effects on prepulse inhibition in rats. Psychopharmacology (Berl.), 231(1): 269–281. doi:10.1007/s00213-013-3234-2.PMID:23954911.
14. Frantz, K.J., Hansson, K.J., Stouffer, D.G., and Parsons, L.H. 2002. 5-HT6 receptor antagonism potentiates the behavioral and neurochemical effects of amphetamine but not cocaine. Neuropharmacology, 42(2): 170–180. doi:10.1016/S0028-3908(01)00165-4.PMID:11804613.
15. Gravius, A., Laszy, J., Pietraszek, M., Saghy, K., Nagel, J., Chambon, C., et al. 2011.Effects of 5-HT6 antagonists, Ro-4368554 and SB-258585, in tests used for the detection of cognitive enhancement and antipsychotic-like activity. Behav. Pharmacol. 22(2): 122–135. doi:10.1097/FBP.0b013e328343d804.PMID:21301322.
16. Gruber, O., Chadha Santuccione, A., and Aach, H. 2014.Magnetic resonance imaging in studying schizophrenia, negative symptoms, and the glutamate system. Front. Psychiatry, 5: 32. doi:10.3389/fpsyt.2014.00032.PMID:24765078.
17. Gupta, A., Dadheech, G., Yadav, D., Sharma, P., and Gautam, S. 2014.Metabolic issues in schizophrenic patients receiving antipsychotic treatment. Indian J. Clin. Biochem. 29(2): 196–201. doi:10.1007/s12291-013-0415-z. PMID:24757302.
18. Gurevich, E.V., and Joyce, J.N. 1997.Alterations in the cortical serotonergic system in schizophrenia: a postmortem study. Biol. Psychiatry, 42(7): 529–545. doi:10.1016/S0006-3223(97)00321-1.PMID:9376449.
19. Haleem, D.J. 2013.Extending therapeutic use of psychostimulants: focus on serotonin-1A receptor. Prog. Neuropsychopharmacol. Biol. Psychiatry, 46: 170–180. doi:10.1016/j.pnpbp.2013.07.015.PMID:23906987.
20. Halford, J.C., Harrold, J.A., Boyland, E.J., Lawton, C.L., and Blundell, J.E. 2007.Serotonergic drugs: effects on appetite expression and use for the treatment of obesity. Drugs, 67(1): 27–55. doi:10.2165/00003495-200767010-00004.PMID: 17209663.
21. Hatcher, P.D., Brown, V.J., Tait, D.S., Bate, S., Overend, P., Hagan, J.J., and Jones, D.N. 2005. 5-HT (6) receptor antagonists improve performance in an attentional set shifting task in rats. Psychopharmacology (Berl.), 181(2): 253–259. doi:10.1007/s00213-005-2261-z.PMID:15846482.
22. Heal, D.J., Smith, S.L., Fisas, A., Codony, X., and Buschmann, H. 2008.Selective 5-HT6 receptor ligands: progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders. Pharmacol. Ther. 117(2): 207–231. doi:10.1016/j.pharmthera.2007.08.006.PMID:18068807.
23. Hjorth, S., Bengtsson, H.J., Milano, S., Lundberg, J.F., and Sharp, T. 1995.Studies on the role of 5-HT1A autoreceptors and alpha 1-adrenoceptors in the inhibition of 5-HT release. I. BMY7378 and prazosin. Neuropharmacology, 34(6): 615–620.PMID:7566497.
24. Leng, A., Ouagazzal, A., Feldon, J., and Higgins, G.A. 2003.Effect of the 5-HT receptor antagonists. Ro04-6790 and Ro65-7199 on latent inhibition and prepulse inhibition in the rat: comparison to clozapine. Pharmacol. Biochem. Behav. 75(2): 281–288. doi:10.1016/S0091-3057(03)00082-0.PMID:12873617.
25. Lopez-Gil, X., Artigas, F., and Adell, A. 2010.Unraveling monoamine receptors involved in the action of typical and atypical antipsychotics on glutamatergic and serotonergic transmission in prefrontal cortex. Curr. Pharm. Des. 16(5): 502–515. doi:10.2174/138161210790361416.PMID:19909228.
26. Lopez-Gil, X., Jimenez-Sanchez, L., Romon, T., Campa, L., Artigas, F., and Adell, A. 2012.Importance of inter-hemispheric prefrontal connection in the effects of non-competitive NMDA receptor antagonists. Int. J. Neuropsychopharmacol. 15(7): 945–956. doi:10.1017/S1461145711001064.PMID:21733285.
27. Loscher, W., and Honack, D. 1993.Effects of the novel 5-HT1A receptor antagonist, (+)-WAY 100135, on stereotyped behavior induced by the NMDA receptor antagonist dizocilpine in rats. Eur. J. Pharmacol. 242(1): 99–104. doi:10.1016/0014-2999(93)90015-A.PMID:8223942.
28. Malhotra, A.K., Pinals, D.A., Adler, C.M., Elman, I., Clifton, A., Pickar, D., and Breier, A. 1997.Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology, 17(3): 141–150. doi:10.1016/S0893-133X(97)00036-5.PMID:9272481.
29. Marcos, B., Chuang, T., Gil-Bea, F.J., and Ramirez, M.J. 2008.Effects of 5-HT6 receptor antagonism and cholinesterase inhibition in models of cognitive impairment in the rat. Br. J. Pharmacol. 155(3): 434–440. doi:10.1038/bjp.2008.281.PMID:18622410.
30. Mathe, J.M., Nomikos, G.G., Hildebrand, B.E., Hertel, P., and Svensson, T.H. 1996.Prazosin inhibits MK-801-induced hyperlocomotion and dopamine release in the nucleus accumbens. Eur. J. Pharmacol. 309(1): 1–11. doi:10.1016/0014-2999(96)00315-9.PMID:8864686.
31. McOmish, C.E., Lira, A., Hanks, J.B., and Gingrich, J.A. 2012.Clozapine-induced locomotor suppression is mediated by 5-HT2A receptors in the forebrain. Neuropsychopharmacology, 37(13): 2747–2755. doi:10.1038/npp.2012.139.PMID: 22871913.
32. Meltzer, H.Y. 1999.The role of serotonin in antipsychotic drug action. Neuropsychopharmacology, 21(2 Suppl.): 106S–115S. doi:10.1016/S0893-133X(99)00046-9.PMID:10432496.
33. Meltzer, H.Y. 2012.Serotonergic mechanisms as targets for existing and novel antipsychotics. Handb. Exp. Pharmacol. 212: 87–124. doi:10.1007/978-3-642- 25761-2_4.PMID:23129329.
34. Meltzer, H.Y., and McGurk, S.R. 1999.The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr. Bull. 25(2): 233–255.PMID:10416729.
35. Mitchell, E.S., and Neumaier, J.F. 2008. 5-HT6 receptor antagonist reversal of emotional learning and prepulse inhibition deficits induced by apomorphine or scopolamine. Pharmacol. Biochem. Behav. 88(3): 291–298. doi:10.1016/j.pbb.2007.08.015.PMID:17920665.
36. Mohler, E.G., Baker, P.M., Gannon, K.S., Jones, S.S., Shacham, S., Sweeney, J.A., and Ragozzino, M.E. 2012.The effects of PRX-07034, a novel 5-HT6 antagonist, on cognitive flexibility and working memory in rats. Psychopharmacology, 220: 687–696. doi:10.1007/s00213-011-2518-7.PMID:21989804.
37. Nakaya, K., Nakagawasai, O., Arai, Y., Onogi, H., Sato, A., Niijima, F., et al. 2011.Pharmacological characterizations of memantine-induced disruption of prepulse inhibition of the acoustic startle response in mice: involvement of dopamine D2 and 5-HT2A receptors. Behav. Brain Res. 218(1): 165–173. doi:10.1016/j.bbr.2010.11.053.PMID:21130810.
38. Ninan, I., and Kulkarni, S.K. 1998. 5-HT2A receptor antagonists block MK-801- induced stereotypy and hyperlocomotion. Eur. J. Pharmacol. 358(2): 111–116. doi:10.1016/S0014-2999(98)00591-3.PMID:9808259.
39. Patel, S., Fernandez-Garcia, E., Hutson, P.H., and Patel, S. 2001.An in vivo binding assay to determine central alpha(1)-adrenoceptor occupancy using [(3)H]prazosin. Brain Res. Brain Res. Protoc. 8(3): 191–198. doi:10.1016/S1385-299X(01)00110-6.PMID:11733195.
40. Perez-Garcia, G., and Meneses, A. 2005.Oral administration of the 5-HT6 receptor antagonists SB-357134 and SB-399885 improves memory formation in an autoshaping learning task. Pharmacol. Biochem. Behav. 81: 673–682. doi:10.1016/j.pbb.2005.05.005.PMID:15964617.
41. Pichat, P., Bergis, O.E., Terranova, J.P., Urani, A., Duarte, C., Santucci, V., et al. 2007.SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia. Neuropsychopharmacology, 32(1): 17–34. doi:10.1038/sj.npp.1301188.PMID:16936709.
42. Pitsikas, N., Zisopoulou, S., Pappas, I., and Sakellaridis, N. 2008.The selective5-HT (6) receptor antagonist Ro 04-6790 attenuates psychotomimetic effects of the NMDA receptor antagonist MK801.Behav. Brain Res. 188(2): 304–309. doi:10.1016/j.bbr.2007.11.010.PMID:18164078.
43. Pouzet, B., Didriksen, M., and Arnt, J. 2002.Effects of the 5-HT6 receptor antagonist, SB-271046, in animal models for schizophrenia. Pharmacol. Biochem. Behav. 71(4): 635–643. doi:10.1016/S0091-3057(01)00743-2.PMID:11888555.
44. Riemer, C., Borroni, E., Levet-Trafit, B., Martin, J.R., Poli, S., and Porter, R.H. 2003.Influence of the 5-HT6 receptor on acetylcholine release in the cortex: pharmacological characterization of 4-(2-bromo-6-pyrrolidin-1-ylpyridine- 4-sulfonyl)phenylamine, a potent and selective 5-HT6 receptor antagonist. J. Med. Chem. 46(7): 1273–1276. doi:10.1021/jm021085c.
45. PMID:12646038.
46. Rouquier, L., Claustre, Y., and Benavides, J. 1994.Alpha 1-adrenoceptor antagonists differentially control serotonin release in the hippocampus and striatum: a microdialysis study. Eur. J. Pharmacol. 261: 59–64. doi:10.1016/ 0014-2999(94)90300-X. PMID:8001654.
47. Schreiber, R., Vivian, J., Hedley, L., Szczepanski, K., Secchi, R.L., Zuzow, M., et al. 2007.Effects of the novel 5-HT (6) receptor antagonist RO4368554 in rat models for cognition and sensorimotor gating. Eur. Neuropsychopharmacol. 7(4): 277–288. doi:10.1016/j.euroneuro.2006.06.009.PMID:16989988.
48. Selvaraj, S., Arnone, D., Cappai, A., and Howes, O. 2014.Alterations in the serotonin system in schizophrenia: A systematic review and meta-analysis of postmortem and molecular imaging studies. Neurosci. Biobehav. Rev. 45C: 233–245. doi:10.1016/j.neubiorev.2014.06.005.PMID:24971825.
49. Sumiyoshi, T., Stockmeier, C.A., Overholser, J.C., Dilley, G.E., and Meltzer, H.Y. 1996.Serotonin1A receptors are increased in postmortem prefrontal cortex in schizophrenia. Brain Res. 708(1–2): 209–214. doi:10.1016/0006-8993(95) 01361-X. PMID:8720882.
50. Vollenweider, F.X., Vontobel, P., Hell, D., and Leenders, K.L. 1999. 5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man–a PET study with [11C]raclopride. Neuropsychopharmacology, 20(5): 424–433. doi:10.1016/S0893-133X(98)00108-0.PMID:10192823.
51. Woolley, M.L., Marsden, C.A., Sleight, A.J., and Fone, K.C. 2003.Reversal of a cholinergic-induced deficit in a rodent model of recognition memory by the selective 5-HT6 receptor antagonist, Ro 04-6790.Psychopharmacology (Berl.), 170(4): 358–367. doi:10.1007/s00213-003-1552-5.PMID:13680084.
52. Woolley, M.L., Marsden, C.A., and Fone, K.C. 2004. 5-HT6 receptors. Curr. Drug Targets CNS Neurol. Disord. 3(1): 59–79. doi:10.2174/1568007043482561.PMID: 14965245